Infectious Issues in Face Transplantation

  • Robin Avery
  • Chad R. Gordon
  • Maria Z. Siemionow


Guidelines for infection prevention and management in solid organ transplant recipients have been published by the American Society of Transplantation. The classic principles of infection after solid organ transplantation, articulated by Rubin many years ago, continue to provide a framework for understanding the infection risk of the individual transplant recipient. Infectious risks that apply to all solid organ transplant candidates are considerations for face transplant recipients as well. In addition to these general principles, each kind of organ transplant has its own particular anatomic and functional considerations that have an impact on infection risk. Some risks can be reduced by careful pre-transplant screening, updating of immunizations, and patient education. However, the infection complication risk following face transplantation is still in its incipient stage. Future research is needed to define the optimal prevention strategy and duration of prophylaxis following face transplantation.


Transplant Recipient Solid Organ Transplant Recipient Peripherally Insert Central Catheter Deep Surgical Site Infection Face Transplant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



American Society of Transplantation Infectious Diseases


Community-Acquired Pneumonia


Clostridium difficile–Associated Diarrhea




Central Nervous System


Epstein–Barr Virus


Hospital-Acquired Pneumonia


Hepatitis B Virus


Hepatitis C Virus


Human Herpes Virus


Herpes Simplex Virus


Latent Tuberculosis Infection


Methicillin-Resistant Staphylococcus Aureus


Peripherally Inserted Central Catheter


Post-Transplant Proliferative Disorder


Ventilator-Associated Pneumonia


Vacomycin-Resistant Enterococcous


Varicella-Zoster Virus


  1. 1.
    American Society of Transplantation Infectious Disease Community of Practice. Guidelines for the management and prevention of infectious complications after solid organ transplantation. Am J Transplant. 2009;9(suppl 4):S1-S257.Google Scholar
  2. 2.
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751.PubMedCrossRefGoogle Scholar
  3. 3.
    Mawhorter SD, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13:581-585.PubMedGoogle Scholar
  4. 4.
    Riddle DJ, Dubberke E. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13:592-600.PubMedCrossRefGoogle Scholar
  5. 5.
    Gordon C, Siemionow M, Papay F, et al. The world’s experience with facial transplantation: what have we learned thus far? Ann Plast Surg. 2009;63:572-578.PubMedCrossRefGoogle Scholar
  6. 6.
    Kalil A, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870-880.PubMedGoogle Scholar
  7. 7.
    Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation. 2005;79:85-90.PubMedCrossRefGoogle Scholar
  8. 8.
    Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.PubMedCrossRefGoogle Scholar
  9. 9.
    Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989;261:3607-3609.PubMedCrossRefGoogle Scholar
  10. 10.
    Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620.PubMedCrossRefGoogle Scholar
  11. 11.
    Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152:761-769.PubMedGoogle Scholar
  12. 12.
    Lantieri L, Meningaud J-P, Grimbert P, et al. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet. 2008;372:639-645.PubMedCrossRefGoogle Scholar
  13. 13.
    Schneeberger S, Lucchina S, Lanzetta M, et al. Cytomegalovirus-related complications in human hand transplantation. Transplantation. 2005;80:441-447.PubMedCrossRefGoogle Scholar
  14. 14.
    Painter W, Mossad S, Siemionow M, et al. First use of CMX001, a novel antiviral drug, for the suppression of cytomegalovirus infection in solid organ transplant patients: A case series. American Transplant Congress 2010, oral late-breaking abstract presentation; 2010; San Diego, CA.Google Scholar
  15. 15.
    Dubernard J-M, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med. 2007;357:2451-2460.PubMedCrossRefGoogle Scholar
  16. 16.
    Devauchelle B, Badet L, Lengele B, et al. First human face allograft: early report. Lancet. 2006;368:203-209.PubMedCrossRefGoogle Scholar
  17. 17.
    Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis. 2009;49:710-716.PubMedCrossRefGoogle Scholar
  18. 18.
    Singh N, Lortholary O, Alexander BD, et al. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome. Transplantation. 2005;80:1131-1133.PubMedCrossRefGoogle Scholar
  19. 19.
    Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003;37:221-229.PubMedCrossRefGoogle Scholar
  20. 20.
    Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2009;9(suppl 4):S258-S262.PubMedCrossRefGoogle Scholar
  21. 21.
    Avery RK, Michaels MG. Strategies for safe living following solid organ transplantation. Am J Transplant. 2009;9(suppl 4):S252-S257.PubMedCrossRefGoogle Scholar
  22. 22.
    Kotton CN, Hibberd PL. Travel medicine and the solid organ transplant recipient. Am J Transplant. 2009;9(suppl 4):S273-S281.PubMedCrossRefGoogle Scholar
  23. 23.
    Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: a 2-year follow-up study. Lancet. 2008;372:631-638.PubMedCrossRefGoogle Scholar
  24. 24.
    Siemionow MZ, Papay F, Djohan R, Bernard S, Gordon CR, et al. First U.S. near-total human face transplantation: a paradigm shift for massive complex injuries. Plast Reconstr Surg. 2010;125:111-122.PubMedGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Robin Avery
    • 1
  • Chad R. Gordon
  • Maria Z. Siemionow
  1. 1.Department of Infectious DiseaseMedicine Institute, Cleveland ClinicClevelandUSA

Personalised recommendations